Ajanta Pharma's legal counsel, Gaurang Shah, has disputed the news that the company has been subject to an import alert from the USFDA for its Aurangabad plant. Multiple news outlets had reported that the company's plant in Aurangabad has been subjected to an import alert - based on news published on the FDA website. The company's stock has plunged in trading since the news.
However, Ajanta Pharma says that "no import alert has been issued" on the firm or its plant facilities.